A detailed history of State Street Corp transactions in Bio Atla, Inc. stock. As of the latest transaction made, State Street Corp holds 139,606 shares of BCAB stock, worth $240,122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
139,606
Previous 139,606 -0.0%
Holding current value
$240,122
Previous $191,000 28.27%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.37 - $3.92 $892,790 - $2.55 Million
-651,672 Reduced 82.36%
139,606 $191,000
Q1 2024

May 15, 2024

BUY
$1.88 - $3.46 $125,788 - $231,505
66,909 Added 9.24%
791,278 $2.72 Million
Q3 2023

Nov 14, 2023

BUY
$1.7 - $3.07 $20,570 - $37,147
12,100 Added 1.7%
724,369 $1.23 Million
Q2 2023

Aug 14, 2023

BUY
$2.83 - $3.87 $1.64 Million - $2.24 Million
579,063 Added 434.71%
712,269 $2.14 Million
Q1 2023

May 15, 2023

BUY
$2.3 - $8.25 $31,279 - $112,200
13,600 Added 11.37%
133,206 $356,000
Q4 2022

Feb 14, 2023

BUY
$6.29 - $11.01 $251,600 - $440,400
40,000 Added 50.25%
119,606 $986,000
Q3 2022

Nov 15, 2022

BUY
$2.94 - $11.87 $69,384 - $280,132
23,600 Added 42.14%
79,606 $613,000
Q2 2022

Aug 15, 2022

SELL
$2.13 - $5.38 $487,674 - $1.23 Million
-228,955 Reduced 80.35%
56,006 $160,000
Q1 2022

May 16, 2022

SELL
$4.38 - $18.78 $3.69 Million - $15.8 Million
-841,960 Reduced 74.71%
284,961 $1.43 Million
Q4 2021

Feb 14, 2022

BUY
$19.0 - $30.95 $3.48 Million - $5.67 Million
183,152 Added 19.41%
1,126,921 $22.1 Million
Q3 2021

Nov 15, 2021

BUY
$29.44 - $43.74 $8.72 Million - $13 Million
296,300 Added 45.76%
943,769 $27.8 Million
Q2 2021

Aug 16, 2021

BUY
$38.07 - $56.17 $18.2 Million - $26.8 Million
477,387 Added 280.68%
647,469 $27.4 Million
Q1 2021

May 17, 2021

BUY
$32.41 - $70.91 $5.51 Million - $12.1 Million
170,082 New
170,082 $8.65 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $62.4M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.